Published ahead of print on January 31, 2008, doi:10.1164/rccm.200708-1251OC
© 2008 American Thoracic Society doi: 10.1164/rccm.200708-1251OC
Antisense Therapy against CCR3 and the Common Beta Chain Attenuates Allergen-induced Eosinophilic Responses1 Department of Medicine, McMaster University, Hamilton, Ontario, Canada; 2 Institut de Cardiologie et de Pneumologie de l'Université Laval, Hôpital Laval, Quebec City, Quebec, Canada; 3 Division of Respiratory Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada; 4 University of Montreal, Montreal, Quebec, Canada; and 5 Topigen Pharmaceuticals, Montreal, Quebec, Canada Correspondence and requests for reprints should be addressed to Gail Gauvreau, Ph.D., HSC 3U25, McMaster University, 1200 Main Street West, Hamilton, ON, Canada L8N 3Z5. E-mail: gauvreau{at}mcmaster.ca Rationale: The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common beta chain (βc) of IL-3, IL-5, and granulocyte-macrophage colony–stimulating factor receptors. Objectives: This study examined the effects of inhaled TPI ASM8 on sputum cellular influx, CCR3 and βc mRNA and protein levels, and the airway physiologic response after inhaled allergen. Methods: Seventeen subjects with mild atopic asthma were randomized in a crossover study to inhale 1,500 µg TPI ASM8 or placebo by nebulizer, once daily for 4 days. On Day 3, subjects underwent allergen inhalation challenge. Sputum samples were collected before and after allergen. CCR3 and βc protein levels were measured by flow cytometry, mRNA was measured using real-time quantitative polymerase chain reaction, and the FEV1 was measured over 7 hours after challenge. Measurements and Main Results: Compared with placebo, TPI ASM8 inhibited sputum eosinophil influx by 46% (P = 0.02) and blunted the increase in total cells (63%) after allergen challenge. TPI ASM8 significantly reduced the early asthmatic response (P = 0.04) with a trend for the late asthmatic response (P = 0.08). The allergen-induced (Day 2 to Day 3) levels of βc mRNA and CCR3 mRNA in sputum-derived cells were inhibited by TPI ASM8 (P = 0.039 and P = 0.054, respectively), with no significant effects on the cell surface protein expression of CCR3 and βc (P > 0.05). No serious adverse events were reported. Conclusions: TPI ASM8 attenuates the allergen-induced increase in target gene mRNA and airway responses in subjects with mild asthma. Clinical trial registered with www.clinicaltrials.gov (NCT 00264966).
Key Words: antisense oligonucleotides • eosinophils • allergen inhalation • airway inflammation
This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
